PD-(L)1 x VEGF Bispecific Plus ADC Combos Progress In Leaps And Bounds In 2025

 
• By Dexter Jie Yan
  
PD-(L)1/VEGF-targeting bispecific antibodies combined with antibody-drug conjugates are advancing by leaps and bounds in the clinic. (Shutterstock)

More from Clinical Trials

More from R&D